# A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

> **NCT00996203** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 201 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]
- **DRUG:** DMARDs (disease-modifying antirheumatic drugs)

## Key facts

- **NCT ID:** NCT00996203
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-31
- **Primary completion:** 2011-02-14
- **Final completion:** 2011-02-14
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996203, "A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00996203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*